olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
Published 2 years ago • 413 plays • Length 3:41Download video MP4
Download video MP3
Similar videos
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
1:37
olaparib plus abiraterone for mcrpc: are biomarkers necessary?
-
5:36
propel trial
-
5:12
magnitude shows benefit of add-on niraparib for mutated mcrpc | gerhardt attard
-
5:59
peace-1 points to benefit of adding abiraterone to adt–docetaxel in de novo mcspc | karim fizazi
-
6:39
latitude supports first-line abiraterone use for metastatic prostate cancer | kim chi
-
9:59
profound performance: olaparib vs. enzalutamide or abiraterone for hrr altered mcrpc
-
1:34
combination therapies for the treatment of prostate cancer
-
10:21
profound: olaparib vs enzalutamide or abiraterone for mcrpc with hrr gene alterations
-
6:42
titan trial
-
5:20
add-on parp inhibition in metastatic crpc: propel and magnitude | david vanderweele
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
4:30
profound: olaparib for hrr mcrpc
-
1:11
dr. burgess on the synergy between abiraterone and adt in prostate cancer
-
6:12
peace-1 trial
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer